Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Blackstone, BlackRock, Apollo Global Management, Novo Nordisk A/S, Welltower, Prologis, and Venture Global are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and ...
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Hikma launched liraglutide, a generic version of an earlier Novo Nordisk weight loss drug, in the US in December. Liraglutide, which Novo sells as Victoza for diabetes and Saxenda for weight loss, has ...
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback